Literature DB >> 1698863

Functional epitope analysis of the human CD4 molecule. The MHC class II-dependent activation of resting T cells is inhibited by monoclonal antibodies to CD4 regardless whether or not they recognize epitopes involved in the binding of MHC class II or HIV gp120.

M Merkenschlager1, D Buck, P C Beverley, Q J Sattentau.   

Abstract

This study was designed to define regions on the human CD4 molecule important for the class II-dependent activation of resting, polyclonal CD4 T cells. With the use of mAb to known epitopes on CD4, we assayed the degree of CD4 saturation and functional effects on T cell activation over a range of antibody concentrations in parallel titration experiments. This approach allows a quantitative comparison of different reagents, regardless of parameters such as affinity for CD4. In sharp contrast to results reported for preactivated T cells and CD4 transfected T cell hybridomas, all 22 CD4 mAb tested did inhibit proliferative responses of freshly isolated CD4 T cells to MHC class II Ag. At the lowest saturating concentration of each antibody, T cell proliferation was reduced by 45 to 82%. Inhibition did not depend on antibody-induced modulation of CD4 expression. Strikingly, no correlation was found between the functional effects and the specificity of the mAb for different epitopes on CD4, such as the putative binding sites for MHC class II or HIV glycoprotein gp120.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1698863

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  10 in total

1.  Quantitative immunofluorescent assay of full-length, recombinant CD4 in solution and mapping of its epitopes.

Authors:  P F Tosi; H Benoist; C Nicolau
Journal:  J Fluoresc       Date:  1991-06       Impact factor: 2.217

2.  Targeted transduction via CD4 by a lentiviral vector uses a clathrin-mediated entry pathway.

Authors:  Min Liang; Kouki Morizono; Nonia Pariente; Masakazu Kamata; Benhur Lee; Irvin S Y Chen
Journal:  J Virol       Date:  2009-09-30       Impact factor: 5.103

3.  Discovery and Characterization of a Novel CD4-Binding Adnectin with Potent Anti-HIV Activity.

Authors:  David Wensel; Yongnian Sun; Zhufang Li; Sharon Zhang; Caryn Picarillo; Thomas McDonagh; David Fabrizio; Mark Cockett; Mark Krystal; Jonathan Davis
Journal:  Antimicrob Agents Chemother       Date:  2017-07-25       Impact factor: 5.191

4.  The T cell antigen receptor CD3:CD4 molecular complex is diminished on the surface of pulmonary lymphocytes.

Authors:  K Marathias; C Pinto; G Rodberg; F Preffer; J Wong; R Kradin
Journal:  Am J Pathol       Date:  1994-11       Impact factor: 4.307

5.  Association of T cell and macrophage dysfunction with surface gp 120-immunoglobulin-complement complexes in HIV-infected patients.

Authors:  V Daniel; C Süsal; R Weimer; R Zimmermann; A Huth-Kühne; G Opelz
Journal:  Clin Exp Immunol       Date:  1993-08       Impact factor: 4.330

6.  Analysis of the basis of resistance and susceptibility of CD4+ T cells to human immunodeficiency virus (HIV)-gp120 induced anergy.

Authors:  A Faith; R E O'Hehir; M Malkovsky; J R Lamb
Journal:  Immunology       Date:  1992-06       Impact factor: 7.397

7.  Oral immunization of macaques with attenuated vaccine virus induces protection against vaginally transmitted AIDS.

Authors:  S V Joag; Z Q Liu; E B Stephens; M S Smith; A Kumar; Z Li; C Wang; D Sheffer; F Jia; L Foresman; I Adany; J Lifson; H M McClure; O Narayan
Journal:  J Virol       Date:  1998-11       Impact factor: 5.103

8.  Safety, pharmacokinetics, and antiretroviral activity of multiple doses of ibalizumab (formerly TNX-355), an anti-CD4 monoclonal antibody, in human immunodeficiency virus type 1-infected adults.

Authors:  Jeffrey M Jacobson; Daniel R Kuritzkes; Eliot Godofsky; Edwin DeJesus; Jeffrey A Larson; Steven P Weinheimer; Stanley T Lewis
Journal:  Antimicrob Agents Chemother       Date:  2008-11-17       Impact factor: 5.191

Review 9.  The antiviral activity of antibodies in vitro and in vivo.

Authors:  P W Parren; D R Burton
Journal:  Adv Immunol       Date:  2001       Impact factor: 3.543

Review 10.  Clinical development of monoclonal antibody-based drugs in HIV and HCV diseases.

Authors:  Michela Flego; Alessandro Ascione; Maurizio Cianfriglia; Stefano Vella
Journal:  BMC Med       Date:  2013-01-04       Impact factor: 8.775

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.